Atogepant for Episodic Migraine Prevention: Phase 3 Data Atogepant for Episodic Migraine Prevention: Phase 3 Data

Results of the ELEVATE trial demonstrating the safety and efficacy of oral atogepant for the prevention of treatment-resistant episodic migraine prevention have now been published.Medscape Medical News

Source: Medscape Neurology and Neurosurgery Headlines - March 8, 2024 Category: Neurology Tags: Neurology & Neurosurgery Source Type: news